Cybin Gestione

Criteri Gestione verificati 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Michael Halstead

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	4.9yrs
Durata media del Consiglio di amministrazione	5.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Nuova narrativa • Mar 20

Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results

It sounds like Cybin (CYBN) is gaining serious traction in the psychedelic therapy space! Guggenheim’s $35 price target is pretty aggressive, considering the stock is currently trading at a fraction o

AMMINISTRATORE DELEGATO

Michael Halstead (53 yo)

less than a year

Mandato

Mr. Michael I. Halstead, J.D., serves as Chief Executive Officer at Cybin Inc. since August 3, 2026. He is President at Intra-Cellular Therapies, Inc. since March 19, 2024 and had been its General Counsel...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric So	Co-Founder	5.8yrs	US$13.57m	6.18% CA$ 81.3m
Paul Glavine	Co-Founder	no data	US$13.56m	6.14% CA$ 80.6m
Greg Cavers	Chief Financial Officer	5.8yrs	US$1.22m	0.17% CA$ 2.3m
Aaron Bartlone	Chief Operating Officer	3.2yrs	US$1.22m	0.31% CA$ 4.0m
Amir Inamdar	Chief Medical Officer	4.9yrs	US$1.32m	0.31% CA$ 4.0m
Michael Halstead	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
John Kanakis	Co-Founder	no data	US$1.19m	Nessun dato
Alex Nivorozhkin	Chief Scientific Officer	5.8yrs	Nessun dato	Nessun dato
Lori Challenger	Chief Compliance	4.9yrs	Nessun dato	Nessun dato
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.8yrs	US$1.12m	0.24% CA$ 3.2m
Sara Somerset	Chief Communications Officers	no data	Nessun dato	Nessun dato
Regina Donohue	Chief People Officer	less than a year	Nessun dato	Nessun dato

4.9yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di HELP è considerato esperto (durata media dell'incarico 4.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric So	Co-Founder	5.8yrs	US$13.57m	6.18% CA$ 81.3m
Paul Glavine	Co-Founder	5.8yrs	US$13.56m	6.14% CA$ 80.6m
Robert S. Langer	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Theresa Firestone	Lead Independent Director	5.1yrs	US$239.50k	0.11% CA$ 1.4m
Freda Lewis-Hall	Independent Director & Chair of Scientific Advisory Committee	less than a year	US$339.01k	0.16% CA$ 2.2m
Mark Lawson	Independent Director	5.8yrs	US$239.50k	0.21% CA$ 2.8m
Grant Froese	Independent Director	5.8yrs	US$224.50k	0.21% CA$ 2.8m
Stephen Brannan	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Andrew Cutler	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Suresh Durgam	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Eric Hoskins	Independent Director	5.8yrs	US$224.50k	0.21% CA$ 2.8m

5.1yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HELP sono considerati esperti (durata media dell'incarico 5.1 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/09/14 18:58
Prezzo dell'azione a fine giornata	2026/09/11 00:00
Utili	2026/06/30
Utili annuali	2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Cybin Inc. è coperta da 15 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Co-Founder recently bought CA$1.7m worth of stock

Chief Operating Officer recently sold CA$504k worth of stock

High number of new directors

Helus Pharma Announces Management Changes

Cybin Inc., Annual General Meeting, Sep 22, 2026

Chief Financial Officer recently sold CA$609k worth of stock

Recent updates

Co-Founder recently bought CA$1.7m worth of stock

Chief Operating Officer recently sold CA$504k worth of stock

High number of new directors

Helus Pharma Announces Management Changes

New major risk - Financial position

New minor risk - Share price stability

Cybin Inc., Annual General Meeting, Sep 22, 2026

Helus Pharma Completes Enrollment In APPROACH Phase 3 Pivotal Study Of HLP003 In Adjunctive Treatment Of Major Depressive Disorder

Chief Financial Officer recently sold CA$609k worth of stock

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $50.000008 million.

Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress

Helus Pharma Announces Scientific Advisory Board Appointments

New minor risk - Share price stability

Helus Pharma Announces CEO Changes Effective April 20, 2026

Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026

Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought CA$100k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

New minor risk - Profitability

No longer forecast to breakeven

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought CA$87k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

New minor risk - Share price stability

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses